Board of Directors

Robert S. Radie is Chairman and has served as a Director on Rockwell Medical's Board since March 2020.

Mr. Radie has more than three decades of experience working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. Currently, Mr. Radie is Chairman and CEO of Neuraptive Therapeutics. Previously he served as President, CEO and Director of Zyla Life Sciences (formerly Egalet) from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in 2011. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular, Inc. from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick Pharmaceuticals, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company.

In addition to his role as Chairman of the Board of Rockwell Medical, Mr. Radie also serves as Chairman of the Board at Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie served as a Director of Paratek Pharmaceuticals, Inc., Affinium Pharmaceuticals, Ltd. and Veloxis Pharmaceuticals AS.

Mr. Radie received his B.S. in Chemistry from Boston College.

​

John Cooper has served as a Director on Rockwell Medical's Board since September 2017.

Mr. Cooper’s career spans over 30 years of senior executive experience managing publicly-traded companies in the life sciences industry. He has played key leadership roles building companies with transformational medical technologies, including the first FDA approved synthetic peptide-containing pulmonary surfactant for premature infants with severe respiratory disease and the second FDA approved blood diagnostic test for HIV. Mr. Cooper has significant experience in corporate and organization development, raising capital, mergers and acquisitions, strategic alliances, investor relations, and corporate governance. Over his career, Mr. Cooper has raised approximately $1 billion in capital through various financing and strategic transactions. Currently, Mr. Cooper provides corporate development and financial advisory services to emerging public and private companies in the life sciences industry.

Mr. Cooper held executive leadership positions for Windtree Therapeutics (formerly Discovery Laboratories), a specialty biopharmaceutical company focused on respiratory therapeutics, from 2001 to 2016. His roles included President, Chief Executive Officer and Member of the Board of Directors, President and Chief Financial Officer, Executive Vice President and Chief Financial Officer. Prior to Discovery Labs, Mr. Cooper served as Senior Vice President and Chief Financial Officer at Chrysalis International Corporation (acquired by Phoenix Life Sciences) and its predecessor DNX Corporation, where he managed its initial public offering and negotiated and integrated several strategic acquisitions. Previously, Mr. Cooper served in senior financial management and executive committee roles at ENI Diagnostics (acquired by Pharmacia AB).

Mr. Cooper received his B.S. in Commerce from Rider University and holds a CPA designation.

Joe Dawson has served as a Director on Rockwell Medical's Board since November 2025.

Mr. Dawson has more than 25 years' experience in the renal care and cardiovascular markets. Throughout his career, Mr. Dawson has negotiated and secured key customer contracts, acquired companies in new product segments, and driven top- and bottom-line growth. Additionally, his mastery of FDA-regulated markets, global supply chains, and commercialization pathways for medical devices make him an invaluable addition to Rockwell Medical's board of directors as the Company seeks to grow its market share, optimize its manufacturing networks, and pursue business development opportunities.

Most recently, he was President, North America Division at Nipro Medical Corporation, a wholly owned subsidiary of Nipro Corporation. Overseeing one of the largest global medical device manufacturer's U.S. operations, Mr. Dawson's leadership included strategic P&L responsibility, operational oversight, and direct accountability for compliance in highly regulated therapeutic categories including dialysis, vascular access, and infusion technologies. Previously, he held various sales and management positions at Cordis Corporation, a Johnson & Johnson subsidiary at the time and leading developer and manufacturer of interventional vascular technology, specializing in cardiology and endovascular devices like catheters, balloons and stents. Mr. Dawson began his career at W. L. Gore & Associates, a global materials science company known for its innovative products, particularly those made from expanded polytetrafluoroethylene. Mr. Dawson earned a B.S. in Neurobiology from St. John's University.

Joan Lau, Ph.D. has served as a Director on Rockwell Medical's Board since October 2023.

Dr. Lau has more than 20 years’ experience in executive leadership of R&D focused biopharma as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies. Currently, Dr. Lau is CEO of Spirovant, where she is responsible for the strategic direction and growth of the gene therapy company. Previously, Dr. Lau co-founded and was Managing Partner of Militia Hill Ventures, which focuses on building and growing high quality life sciences companies. Dr. Lau led several biotech companies including Azelon Pharmaceuticals as President and CEO; Locus Pharmaceuticals; and Immunome as COO. Additionally, she served as a director of Renovacor (NYSE:RCOR) until its acquisition by Rocket Pharmaceuticals and began her biopharmaceutical career at Merck Research Laboratories.

Engaged in the Philadelphia community, Dr. Lau serves on the Boards of Trustees for the University of Pennsylvania, Brandywine Realty Trust (NYSE:BDN), and the Philadelphia Orchestra. Dr. Lau earned a MBA from the Wharton School of Business and a BSE in Bioengineering, both at the University of Pennsylvania, and a Ph.D. in Neuroscience from the University of Cincinnati College of Medicine.

Allen R. Nissenson, M.D. has served as a Director on Rockwell Medical's Board since June 2020.

Dr. Nissenson has served as Emeritus Chief Medical Officer of DaVita Kidney Care, a division of DaVita HealthCare Partners, since January 2020. He previously served as Chief Medical Officer of DaVita Kidney Care from August 2008 to December 2019. Dr. Nissenson is also currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, where he previously served as Director of the Dialysis Program and Associate Dean. He has served on the board of Angion Biomedica Corp., a late-stage biopharmaceutical company, since January 2020. He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board.

Dr. Nissenson earned his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.

Mark Ravich has served as a Director on Rockwell Medical's Board since June 2017.

Mr. Ravich is the President of Tri-Star Management, which he co-founded in 1998. Additionally, he serves as the chief manager of various real estate entities. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the Chief Executive Officer and a Director of Universal International.

Mr. Ravich received his BSE and MBA, Magna Cum Laude, from the Wharton School of the University of Pennsylvania.

Mark Strobeck, Ph.D. is President and CEO of Rockwell Medical and has served as a Director on the Company's Board since July 2022.

Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years. Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012.

Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.